Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.-论文-万方医学网

第一作者： Yuji,Teraoka

第一单位： 1Department of Gastroenterology and Metabolism, Institute of Biomedical and Health, Hiroshima, Japan.;2Liver Research Project Center, Hiroshima University, Hiroshima, Japan.

作者： Yuji,Teraoka ^[1] ; Takuro,Uchida ^[1] ; Michio,Imamura ^[1] ; Nobuhiko,Hiraga ^[1] ; Mitsutaka,Osawa ^[1] ; Hiromi,Kan ^[1] ; Yuhei,Saito ^[1] ; Masataka,Tsuge ^[2] ; Hiromi,Abe-Chayama ^[3] ; C Nelson,Hayes ^[1] ; Grace Naswa,Makokha ^[1] ; Hiroshi,Aikata ^[1] ; Daiki,Miki ^[4] ; Hidenori,Ochi ^[4] ; Yuji,Ishida ^[5] ; Chise,Tateno ^[5] ; Kazuaki,Chayama ^[6]

作者单位： 1Department of Gastroenterology and Metabolism, Institute of Biomedical and Health, Hiroshima, Japan.;2Liver Research Project Center, Hiroshima University, Hiroshima, Japan. ^[1] 1Department of Gastroenterology and Metabolism, Institute of Biomedical and Health, Hiroshima, Japan.;2Liver Research Project Center, Hiroshima University, Hiroshima, Japan.;3Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan. ^[2] 1Department of Gastroenterology and Metabolism, Institute of Biomedical and Health, Hiroshima, Japan.;2Liver Research Project Center, Hiroshima University, Hiroshima, Japan.;4Center for Medical Specialist Graduate Education and Research, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. ^[3] 2Liver Research Project Center, Hiroshima University, Hiroshima, Japan.;5Laboratory for Digestive Diseases, RIKEN Center for Integrative Medical Sciences, Hiroshima, Japan. ^[4] 2Liver Research Project Center, Hiroshima University, Hiroshima, Japan.;6PhoenixBio Co., Ltd, Higashihiroshima, Japan. ^[5] 1Department of Gastroenterology and Metabolism, Institute of Biomedical and Health, Hiroshima, Japan.;2Liver Research Project Center, Hiroshima University, Hiroshima, Japan.;5Laboratory for Digestive Diseases, RIKEN Center for Integrative Medical Sciences, Hiroshima, Japan. ^[6]

主题词动物(Animals);抗病毒药(Antiviral Agents);苯丙氮|艹卓|类(Benzazepines);氨甲酸酯类(Carbamates);复方合剂(Drug Combinations);抗药性, 病毒(Drug Resistance, Viral);药物疗法, 联合(Drug Therapy, Combination);基因型(Genotype);肝炎病毒属(Hepacivirus);丙型肝炎(Hepatitis C);人类(Humans);咪唑类(Imidazoles);吲哚类(Indoles);异喹啉类(Isoquinolines);小鼠(Mice);蛋白酶抑制药(Protease Inhibitors);吡咯烷类(Pyrrolidines);磺胺类(Sulfonamides);治疗失败(Treatment Failure);缬氨酸(Valine);病毒非结构蛋白质类(Viral Nonstructural Proteins);病毒血症(Viremia)

DOI 10.1099/jgv.0.001091

PMID 29916799

发布时间 2022-01-10

检索历史清除

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.

The Journal of general virology

相似文献

The Journal of general virology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.

The Journal of general virology

相似文献

The Journal of general virology

相关期刊

检索历史清除